Hyku Biosciences Launches With $56M to Advance its Covalent Medicines Platform to Expand the Boundaries of Drug Discovery

Contributed by: ACCESSWIRE

Logo

Tags

Healthcare & Pharmaceutical

Hyku Biosciences, Inc.

Company Update

More Like This

ACCESSWIRE associated0

HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies

PR Newswire associated0

Skyhawk Therapeutics Expands into State-of-the-Art Labs in its Basel, Switzerland Location

GlobeNewswire associated0

4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR

MiLaboratories co-founders: Dmitry Chudakov, Stan Poslavsky, Dmitry Bolotin, Alexey Nechaev (Photo: Business Wire)

MiLaboratories Secures Series A, Raising Total Funding to $10 Million to Revolutionize the World of Genomic Research

Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy

PR Newswire associated0

Tetra Pharm Technologies and Kvantify Announce Partnership to Accelerate the Discovery of Novel Drug Candidates Targeting the Endocannabinoid System

Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases